6th Jan 2021 20:18
Arix Bioscience PLC - healthcare investor based in London - Portfolio company Imara Inc says results from its Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease demonstrated the drug was well tolerated as a monotherapy and in combination with hydroxyurea at all dose levels.
In the second half of 2021, Imara expects to report interim Phase 2b data from ongoing clinical trials in sickle cell disease and beta-thalassemia.
Current stock price: 214.00 pence
Year-to-date change: down 2.3%
By Ife Taiwo; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
ARIX.L